Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 26;12(2):165.
doi: 10.3390/jpm12020165.

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma

Serafeim Chrysovalantis Kotoulas  1 , Ioanna Tsiouprou  1 , Eva Fouka  1 , Athanasia Pataka  1 , Despoina Papakosta  1 , Konstantinos Porpodis  1
Affiliations
Review

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma

Serafeim Chrysovalantis Kotoulas et al. J Pers Med. .

Abstract

Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice questions, concerning its efficacy and safety and its association with other asthma-related and drug-related parameters. Evidence suggests that omalizumab improves asthma control and reduces the incidence and frequency of exacerbations in patients with severe allergic asthma. Omalizumab is also effective in those patients in reducing corticosteroid use and healthcare utilization, while it also seems to improve lung function. Several biomarkers have been recognized in predicting its efficacy in its target group of patients, while the optimal duration for evaluating its efficacy is between 16 and 32 weeks.

Keywords: IgE; omalizumab; severe allergic asthma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Global Initiative for Asthma Global Strategy for Asthma Management and Prevention. 2021. [(accessed on 10 October 2021)]. Available online: www.ginasthma.org.
    1. Johansson S.G., Hourihane J.O., Bousquet J., Bruijnzeel-Koomen C., Dreborg S., Haahtela T., Kowalski M.L., Mygind N., Ring J., van Cauwenberge P., et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56:813–824. doi: 10.1034/j.1398-9995.2001.t01-1-00001.x. - DOI - PubMed
    1. Akar-Ghibril N., Casale T., Custovic A., Phipatanakul W. Allergic endotypes and phenotypes of asthma. J. Allergy Clin. Immunol. Pract. 2020;8:429–440. doi: 10.1016/j.jaip.2019.11.008. - DOI - PMC - PubMed
    1. Wenzel S.E. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat. Med. 2012;18:716–725. doi: 10.1038/nm.2678. - DOI - PubMed
    1. Bel E.H. Clinical phenotypes of asthma. Curr. Opin. Pulm. Med. 2004;10:44–50. doi: 10.1097/00063198-200401000-00008. - DOI - PubMed

LinkOut - more resources